Literature DB >> 6692408

Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.

P Giacomini, F Veglia, P Cordiali Fei, T Rehle, P G Natali, S Ferrone.   

Abstract

Utilizing double-determinant immunoassays (DDIAs), the high-molecular-weight melanoma-associated antigen (HMW-MAA) was detected only in fetal skin and in one nipple of 54 normal tissues from adults tested, while the cytoplasmic MAA recognized by the monoclonal antibody 465. 12S was found in most of the normal tissues tested. Among malignant lesions, the HMW-MAA was found in melanomas, astrocytomas, and skin carcinomas; the cytoplasmic MAA was found in all of the malignant lesions tested, even those which originated from normal tissues without detectable cytoplasmic MAA. The levels of the HMW-MAA and of the cytoplasmic MAA showed marked variations in malignant lesions removed from various patients, as well as in autologous metastatic lesions removed from four patients with melanoma. No relationship was found between the degree of expression of the two MAA analyzed and the clinical stage of the disease. Both types of MAA were found in sera from patients with melanoma or other types of cancers, as well as in sera from healthy donors. The level of the HMW-MAA tended to be higher in patients with Stage IV melanoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Authors:  Fabio Morandi; Maria Valeria Corrias; Isabella Levreri; Paola Scaruffi; Lizzia Raffaghello; Barbara Carlini; Paola Bocca; Ignazia Prigione; Sara Stigliani; Loredana Amoroso; Soldano Ferrone; Vito Pistoia
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

2.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Authors:  A Mittelman; Z J Chen; T Kageshita; H Yang; M Yamada; P Baskind; N Goldberg; C Puccio; T Ahmed; Z Arlin
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma.

Authors:  T Cerny; S E Owens; S A Mackenzie; P M Nuttall; A K Gosh; D B Smith; N Thatcher
Journal:  Eur J Nucl Med       Date:  1987

5.  Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.

Authors:  M Maio; B Gulwani; S Tombesi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts.

Authors:  R L Wahl; B S Wilson; M Liebert; W H Beierwaltes
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Presence of normal human cell surface antigens in plasma of athymic mice bearing a human colon carcinoma and in normal human plasma.

Authors:  Y Markson; D W Weiss; O Weiss; F Doljanski
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.

Authors:  A Mittelman; Z J Chen; H Yang; G Y Wong; S Ferrone
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  In vitro differentiation and antigenic changes in human melanoma cell lines.

Authors:  L Guarini; M Temponi; G M Edwalds; J R Vita; P B Fisher; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Immunodiagnosis of human malignancy.

Authors:  H F Seigler
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.